The Editor's Roundtable: The JUPITER Trial—Initial Results and Clinical Implications

      This CME activity is supported by an educational grant from AstraZeneca, Wilmington, Delaware.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ridker P.M.
        • Danielson E.
        • Fonseca F.A.H.
        • Genest J.
        • Gotto Jr, A.M.
        • Kastelein J.J.P.
        • Koenig W.
        • Libby P.
        • Lorenzatti A.J.
        • MacFadyen J.G.
        • et al.
        Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
        N Engl J Med. 2008; 359: 2195-2207
        • Ridker P.M.
        • Rifai N.
        • Pfeffer M.A.
        • Downs J.R.
        • Weis S.E.
        • Miles J.S.
        • Gotto A.M.
        • Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators
        Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels.
        N Engl J Med. 2001; 344: 1959-1965
        • Downs J.R.
        • Clearfield M.
        • Weis S.
        • Whitney E.
        • Shapiro D.R.
        • Beere P.A.
        • Langendorfer A.
        • Stein E.A.
        • Kruyer W.
        • Gotto Jr, A.M.
        Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS.
        JAMA. 1998; 279: 1615-1622
        • Shepherd J.
        • Cobbe S.M.
        • Ford I.
        • Isles C.G.
        • Lorimer A.R.
        • MacFarlane P.W.
        • McKillop J.H.
        • Packard C.J.
        • West of Scotland Coronary Prevention Study Group
        Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.
        N Engl J Med. 1995; 333: 1301-1307
        • Ridker P.M.
        • Cannon C.P.
        • Morrow D.
        • Rifai N.
        • Rose L.M.
        • McCabe C.H.
        • Pfeffer M.A.
        • Braunwald E.
        C-reactive protein levels and outcomes after statin therapy.
        N Engl J Med. 2005; 352: 20-28
        • Ridker P.M.
        • Rifai N.
        • Pfeffer M.A.
        • Sacks F.M.
        • Moye L.A.
        • Goldman S.
        • Flaker G.C.
        • Braunwald E.
        • Cholesterol and Recurrent Events (CARE) Investigators
        Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels.
        Circulation. 1998; 98: 839-844
        • Nissen S.E.
        • Tuzcu E.M.
        • Schoenhagen P.
        • Crowe T.
        • Sasiela W.J.
        • Tsai J.
        • Orazem J.
        • Magorien R.D.
        • O'Shaughnessy C.
        • Ganz P.
        • Reversal of Atherosclerosis with Aggressive Lipid lowering (REVERSAL) Investigators
        Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease.
        N Engl J Med. 2005; 352: 29-38
        • Morrow D.A.
        • de Lemos J.A.
        • Sabatine M.S.
        • Wiviott S.D.
        • Blazing M.A.
        • Shui A.
        • Rifai N.
        • Califf R.M.
        • Braunwald E.
        Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor trial.
        Circulation. 2006; 114: 281-288
        • Ridker P.M.
        • Morrow D.A.
        • Rose L.M.
        • Rifai N.
        • Cannon C.P.
        • Braunwald E.
        Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial.
        J Am Coll Cardiol. 2005; 45: 1644-1648
        • Arima H.
        • Kubo M.
        • Yonemoto K.
        • Doi Y.
        • Ninomiya T.
        • Tanizaki Y.
        • Hata J.
        • Matsumura K.
        • Iida M.
        • Kiyohara Y.
        High-sensitivity C-reactive protein and coronary heart disease in a general population of Japanese: the Hisayama study.
        Arterioscler Thromb Vasc Biol. 2008; 28: 1385-1391
        • Kastelein J.J.P.
        • Akdim F.
        • Stroes E.S.G.
        • Zwinderman A.H.
        • Bots M.L.
        • Stalenhoef A.F.H.
        • Visseren F.L.J.
        • Sijbrands E.J.G.
        • Trip M.D.
        • Stein E.A.
        • et al.
        Simvastatin with or without ezetimibe in familial hypercholesterolemia.
        N Engl J Med. 2008; 358: 1431-1443